Literature DB >> 1456888

Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.

R Wagner1, H Fliessbach, G Wanner, M Motz, M Niedrig, G Deby, A von Brunn, H Wolf.   

Abstract

Antigens in a particulate conformation were shown to be highly immunogenic in mammals. For this reason, the particle forming capacity of derivatives of the HIV-1 group specific core antigen p55 gag was assayed and compared dependent on various expression systems: recombinant bacteria, vaccinia- and baculoviruses were established encoding the entire core protein p55 either in its authentic sequence or lacking the myristylation consensus signal. Moreover, p55 gag was expressed in combination with the protease (p55-PR) or with the entire polymerase (p55-pol), respectively. Budding of 100-160 nm p55 core particles, resembling immature HIV-virions, was observed in the eucaryotic expression systems only. In comparison to the vaccinia virus driven expression of p55 in mammalian cells, considerably higher yields of particulate core antigen were obtained by infection of Spodoptera frugiperda (Sf9) insect cells with the recombinant Autographa californica nuclear polyhedrosis (AcMNPV) baculovirus. Mutation of the NH2-terminal myristylation signal sequence prevented budding of the immature core particles. Expression of the HIV p55-PR gene construct by recombinant baculovirus resulted in complete processing of the p55 gag precursor molecule in this system. The introduction of an artificial frameshift near the natural frameshift site resulted in constitutive expression of the viral protease and complete processing of p55, both in Escherichia coli and in vaccinia virus infected cells. Interestingly, significant processing of p55 resembling that of HIV infected H9 cells could also be achieved in the vaccinia system by fusing the entire pol gene to the gag gene. Moreover, processing was not found to be dependent on amino-terminal myristylation of the gag procursor molecule, which is in contrast to observations with type C and type D retrovirus. However, complete processing of p55 into p24, p17, p9 and p6 abolished particle formation. Purified immature HIV-virus like particles were highly immunogenic in rabbits, leading to a strong humoral immune response after immunization. Empty immature p55 gag particles represent a noninfectious and attractive candidate for a basic vaccine component.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1456888     DOI: 10.1007/bf01309579

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  41 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

2.  HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides.

Authors:  D F Nixon; A R Townsend; J G Elvin; C R Rizza; J Gallwey; A J McMichael
Journal:  Nature       Date:  1988-12-01       Impact factor: 49.962

3.  Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus.

Authors:  A Rein; M R McClure; N R Rice; R B Luftig; A M Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

4.  The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.

Authors:  R J Mervis; N Ahmad; E P Lillehoj; M G Raum; F H Salazar; H W Chan; S Venkatesan
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Maturation of human immunodeficiency virus, strain LAV, in vitro.

Authors:  T Katsumoto; N Hattori; T Kurimura
Journal:  Intervirology       Date:  1987       Impact factor: 1.763

7.  HIV-specific cytotoxic T lymphocytes in seropositive individuals.

Authors:  B D Walker; S Chakrabarti; B Moss; T J Paradis; T Flynn; A G Durno; R S Blumberg; J C Kaplan; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1987 Jul 23-29       Impact factor: 49.962

8.  Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions.

Authors:  A Lever; H Gottlinger; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

9.  In vivo modification of retroviral gag gene-encoded polyproteins by myristic acid.

Authors:  A M Schultz; S Oroszlan
Journal:  J Virol       Date:  1983-05       Impact factor: 5.103

10.  Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region.

Authors:  T Jacks; H D Madhani; F R Masiarz; H E Varmus
Journal:  Cell       Date:  1988-11-04       Impact factor: 41.582

View more
  12 in total

1.  Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.

Authors:  Chad Cecil; Ande West; Martha Collier; Christy Jurgens; Victoria Madden; Alan Whitmore; Robert Johnston; Dominic T Moore; Ronald Swanstrom; Nancy L Davis
Journal:  Virology       Date:  2007-02-01       Impact factor: 3.616

2.  Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.

Authors:  J zur Megede; M C Chen; B Doe; M Schaefer; C E Greer; M Selby; G R Otten; S W Barnett
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 3.  The gag proteins of human immunodeficiency virus type 1: mechanisms of virus assembly and possibilities for interference.

Authors:  S Modrow; B Kattenbeck; A von Poblotzki; M Niedrig; R Wagner; H Wolf
Journal:  Med Microbiol Immunol       Date:  1994-09       Impact factor: 3.402

4.  Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus.

Authors:  Hae-Mi Nam; Kyung-Sil Chae; Young-Jo Song; Nak-Hyung Lee; Joong-Bok Lee; Seung-Yong Park; Chang-Seon Song; Kun-Ho Seo; Sang-Moo Kang; Min-Chul Kim; In-Soo Choi
Journal:  Arch Virol       Date:  2013-02-08       Impact factor: 2.574

5.  Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.

Authors:  Morgane Rolland; Mark A Jensen; David C Nickle; Jian Yan; Gerald H Learn; Laura Heath; David Weiner; James I Mullins
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

6.  Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation.

Authors:  Christine Ludwig; Andreas Leiherer; Ralf Wagner
Journal:  J Virol       Date:  2008-03-05       Impact factor: 5.103

7.  Flow cytometric immunofluorescence assay for detection of antibodies to human immunodeficiency virus type 1 using insoluble precursor forms of recombinant polyproteins as carriers and antigens.

Authors:  Y W Hu; P Birch; E Balaskas; A Zeibdawi; V Scalia; S A Thériault-Valin; P Gill; M T Aye
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

8.  Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 Gag is substituted by a myristylation signal.

Authors:  P P Lee; M L Linial
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

9.  Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.

Authors:  Carmen Álvarez-Fernández; Alberto Crespo Guardo; Javier García-Pérez; Felipe García; Julia Blanco; Laura Escribà-García; Jose Maria Gatell; Jose Alcamí; Montserrat Plana; Sonsoles Sánchez-Palomino
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

10.  Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media.

Authors:  Alisson Lynch; Ann E Meyers; Anna-Lise Williamson; Edward P Rybicki
Journal:  Virol J       Date:  2012-09-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.